A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients.
Ji Yoon JungHong Jae ChonYoung Jin ChoiSang Eun YeonSeok Young ChoiKyung Hee LeePublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)
This study showed that tapentadol ER was effective for treating patients with moderate to severe cancer pain and neuropathic pain, and therefore it significantly improved the patients' QoL.
Keyphrases
- neuropathic pain
- chronic pain
- end stage renal disease
- pain management
- ejection fraction
- chronic kidney disease
- newly diagnosed
- spinal cord injury
- spinal cord
- clinical trial
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- early onset
- high intensity
- double blind
- squamous cell
- phase ii
- postoperative pain